Niagen Bioscience, Inc. (NAGE) Key Metrics
NAGE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $197.0M
- Enterprise value
- $173.8M
- P/E (TTM)
- 13.1
- Forward P/E
- 21.5
- PEG ratio
- —
- Price / sales
- 1.5 10-yr median 4.6
- Price / book
- 2.9 10-yr median 7.5
- EV / EBITDA
- 16.9
- Dividend yield
- —
- Beta
- 2.02
NAGE key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNAGE valuation Price multiples at each fiscal year-end price.
NAGE returns How much profit the business earns on the capital it uses.
NAGE per-share figures Results divided by the shares outstanding at year-end.
NAGE financial health Debt, liquidity and how easily interest is covered.
NAGE efficiency & capital use Working capital cycle and where the cash goes.
NAGE valuation history
NAGE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NAGE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NAGE cash returned to shareholders
NAGE price vs earnings per share
NAGE key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $543.4M | $423.3M | $107.2M | $117.1M | $251.3M | $293.1M | $245.9M | $188.7M | $262.2M | $123.4M |
| Enterprise value | $481.4M | $381.5M | $83.3M | $101.1M | $228.0M | $278.3M | $229.0M | $166.6M | $217.4M | $122.4M |
| P/E ratio | 31.3 | 49.5 | — | — | — | — | — | — | — | — |
| Price / sales | 4.2 | 4.3 | 1.3 | 1.6 | 3.7 | 4.9 | 5.3 | 6.0 | 12.4 | 5.7 |
| Price / book | 7.1 | 9.2 | 3.8 | 4.1 | 7.9 | 17.8 | 12.0 | 6.9 | 4.9 | 12.4 |
| Price / free cash flow | 41.3 | 35.4 | 15.4 | — | — | — | — | — | — | — |
| Price / operating cash flow | 40.4 | 35.0 | 15.1 | — | — | — | — | — | — | — |
| EV / sales | 3.7 | 3.8 | 1.0 | 1.4 | 3.4 | 4.7 | 4.9 | 5.3 | 10.3 | 5.6 |
| EV / EBITDA | 24.5 | 36.9 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 36.6 | 31.9 | 12.0 | — | — | — | — | — | — | — |
| Earnings yield | 3.2% | 2.0% | −4.6% | −14.1% | −10.8% | −6.8% | −13.1% | −17.7% | −4.3% | −2.4% |
| Free cash flow yield | 2.4% | 2.8% | 6.5% | −13.2% | −9.8% | −3.7% | −8.6% | −11.9% | −4.3% | −3.8% |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — | — | — | — | 0.2% | — | — |
| Share price at fiscal year-end | $6.36 | $5.31 | $1.43 | $1.68 | $3.74 | $4.80 | $4.31 | $3.43 | $5.88 | $3.31 |
| Per share | ||||||||||
| Revenue per share | $1.51 | $1.25 | $1.11 | $1.03 | $1.00 | $0.97 | $0.81 | $0.57 | $0.48 | $0.58 |
| Earnings per share | $0.20 | $0.11 | −$0.07 | −$0.24 | −$0.40 | −$0.33 | −$0.56 | −$0.61 | −$0.26 | −$0.08 |
| Operating cash flow per share | $0.16 | $0.15 | $0.09 | −$0.22 | −$0.36 | −$0.17 | −$0.36 | −$0.38 | −$0.22 | −$0.08 |
| Free cash flow per share | $0.15 | $0.15 | $0.09 | −$0.22 | −$0.37 | −$0.18 | −$0.37 | −$0.41 | −$0.25 | −$0.12 |
| Cash per share | $0.76 | $0.56 | $0.36 | $0.29 | $0.42 | $0.27 | $0.33 | $0.41 | $1.02 | $0.04 |
| Book value per share | $0.90 | $0.58 | $0.38 | $0.41 | $0.47 | $0.27 | $0.36 | $0.49 | $1.21 | $0.27 |
| Tangible book value per share | $0.83 | $0.57 | $0.37 | $0.40 | $0.46 | $0.25 | $0.34 | $0.47 | $1.17 | $0.25 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.01 | $0.03 | $0.03 | $0.05 |
| Debt per share | $0.03 | $0.03 | $0.04 | $0.06 | $0.07 | $0.03 | $0.03 | $0.01 | $0.01 | $0.02 |
| Shares outstanding | 85.4M | 79.7M | 75.0M | 69.7M | 67.2M | 61.1M | 57.1M | 55.0M | 44.6M | 37.3M |
| Change in shares outstanding | +7.2% | +6.3% | +7.5% | +3.8% | +10.0% | +7.0% | +3.7% | +23.3% | +19.6% | +3.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 28.3% | 22.9% | −17.3% | −54.8% | −112.7% | −108.1% | −135.0% | −82.2% | −35.7% | −38.4% |
| Return on invested capital (ROIC) | 145.3% | 169.6% | −51.4% | −139.8% | −428.9% | −613.2% | −573.4% | −373.8% | −144.7% | −32.3% |
| Return on assets (ROA) | 19.9% | 13.9% | −9.1% | −29.6% | −56.4% | −50.7% | −78.0% | −63.5% | −27.6% | −15.2% |
| Return on tangible assets | 17.3% | 12.6% | −9.1% | −31.0% | −47.6% | −53.5% | −82.6% | −81.9% | −18.6% | −15.2% |
| Free cash flow margin | 10.2% | 12.0% | 8.3% | −21.4% | −36.4% | −18.1% | −45.8% | −70.9% | −52.6% | −21.5% |
| Income quality (OCF / net income) | 0.77 | 1.42 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.8M | $2.7M | $3.3M | $4.3M | $4.7M | $1.6M | $1.7M | $310,000 | $506,000 | $599,050 |
| Cash & short-term investments | $64.8M | $44.5M | $27.2M | $20.3M | $28.0M | $16.5M | $18.6M | $22.4M | $45.4M | $1.6M |
| Net debt | −$62.0M | −$41.9M | −$23.9M | −$16.0M | −$23.3M | −$14.9M | −$16.9M | −$22.1M | −$44.9M | −$1.0M |
| Debt / equity | 0.04 | 0.06 | 0.12 | 0.15 | 0.15 | 0.10 | 0.08 | 0.01 | 0.01 | 0.06 |
| Debt / assets | 0.03 | 0.04 | 0.06 | 0.08 | 0.08 | 0.04 | 0.04 | 0.01 | 0.01 | 0.03 |
| Net debt / EBITDA | −3.16 | −4.05 | — | — | — | — | — | — | — | — |
| Current ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 | 2.23 | 2.53 | 7.07 | 1.77 |
| Quick ratio | 3.83 | 3.06 | 1.70 | 1.78 | 2.00 | 1.25 | 1.46 | 1.96 | 6.35 | 0.88 |
| Interest coverage | — | — | — | — | -492.2 | -279.6 | -37.0 | -419.9 | -107.0 | -7.8 |
| Working capital | $76.9M | $46.2M | $28.9M | $28.7M | $31.3M | $15.7M | $18.5M | $22.1M | $49.1M | $6.9M |
| Invested capital | $14.6M | $4.2M | $4.6M | $12.6M | $8.4M | $1.6M | $3.6M | $5.1M | $9.0M | $8.9M |
| Tangible asset value | $70.9M | $45.7M | $27.9M | $28.0M | $30.9M | $15.3M | $19.1M | $25.6M | $52.2M | $9.5M |
| Net current asset value | $66.9M | $41.9M | $23.0M | $21.2M | $22.8M | $10.3M | $13.7M | $21.5M | $48.3M | $6.0M |
| Graham number | $2.02 | $1.18 | — | — | — | — | — | — | — | — |
| Graham net-net per share | $0.61 | $0.41 | $0.16 | $0.12 | $0.19 | $0.04 | $0.11 | $0.27 | $0.97 | $0.01 |
| Capital allocation | ||||||||||
| Share buybacks (net) | $251,000 | $0 | — | — | — | — | — | $404,000 | — | — |
| Dividends + buybacks / free cash flow | 1.9% | 0.0% | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.2% | 0.2% | 0.2% | 0.5% | 0.6% | 0.2% | 1.6% | 4.6% | 6.4% | 8.0% |
| Capex / operating cash flow | 2.2% | 1.3% | 2.1% | — | — | — | — | — | — | — |
| Capex / depreciation | 0.20 | 0.11 | 0.09 | 0.18 | 0.25 | 0.09 | 0.49 | 1.72 | 1.89 | 4.11 |
| Stock-based compensation / revenue | 4.7% | 3.7% | 5.7% | 8.0% | 9.2% | 11.7% | 15.5% | 20.2% | 21.7% | 5.5% |
| R&D / revenue | 4.9% | 6.0% | 5.9% | 6.7% | 5.7% | 5.8% | 9.5% | 17.4% | 18.9% | 11.6% |
| SG&A / revenue | 48.3% | 48.0% | 61.5% | 78.6% | 96.0% | 87.3% | 113.5% | 138.4% | 104.2% | 49.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 24.7 | 23.8 | 30.0 | 34.7 | 21.4 | 15.0 | 26.0 | 56.4 | 96.3 | 69.9 |
| Days of inventory on hand | 116.9 | 113.9 | 162.5 | 176.4 | 177.8 | 176.7 | 175.9 | 165.3 | 233.3 | 260.4 |
| Days payables outstanding | 76.3 | 90.1 | 110.8 | 125.4 | 139.7 | 145.1 | 170.5 | 156.2 | 165.0 | 197.5 |
| Cash conversion cycle (days) | 65.3 | 47.6 | 81.7 | 85.7 | 59.5 | 46.6 | 31.4 | 65.6 | 164.6 | 132.8 |
| Receivables turnover | 14.78 | 15.32 | 12.19 | 10.51 | 17.03 | 24.34 | 14.05 | 6.47 | 3.79 | 5.22 |
| Payables turnover | 4.79 | 4.05 | 3.29 | 2.91 | 2.61 | 2.52 | 2.14 | 2.34 | 2.21 | 1.85 |
| Inventory turnover | 3.12 | 3.21 | 2.25 | 2.07 | 2.05 | 2.07 | 2.07 | 2.21 | 1.56 | 1.40 |
| Asset turnover | 1.48 | 1.62 | 1.53 | 1.29 | 1.40 | 1.51 | 1.12 | 0.60 | 0.51 | 1.13 |
| Average receivables | $8.8M | $6.5M | $6.9M | $6.9M | $4.0M | $2.4M | $3.3M | $4.9M | $5.6M | $4.2M |
| Average payables | $9.7M | $9.4M | $10.0M | $10.1M | $9.9M | $9.5M | $9.6M | $6.6M | $4.8M | $6.1M |
| Average inventory | $14.8M | $11.9M | $14.6M | $14.1M | $12.6M | $11.6M | $9.9M | $7.0M | $6.9M | $8.0M |
| Intangibles / total assets | 5.3% | 0.5% | 0.9% | 1.2% | 1.5% | 2.8% | 3.3% | 3.7% | 2.6% | 2.5% |
Computed from NAGE's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NAGE valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Niagen Bioscience traded at 31.3 times earnings. Based on the latest twelve months, the trailing P/E is 13.1 and the forward P/E is 21.5. Niagen Bioscience earned a return on equity of 28.3% and a return on invested capital of 145.3% in fiscal 2025. It ended the year with $2.8 million of debt and $64.8 million in cash and short-term investments, a net cash position of $62.0 million. It returned $0.3 million to shareholders: $0 in dividends and $0.3 million in share buybacks, 2% of free cash flow. The share count rose 129.1% from 37.3M to 85.4M over 9 years.
See the NAGE income statement, the NAGE chart for price history, or the NAGE stock overview for the latest quote and news.
NAGE key metrics FAQ
What is Niagen Bioscience's P/E ratio?
Niagen Bioscience's trailing P/E ratio is 13.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 21.5. At the end of fiscal 2025 it was 31.3.
What is Niagen Bioscience's EV/EBITDA?
Niagen Bioscience's enterprise value was 24.5 times EBITDA at the end of fiscal 2025 (enterprise value $481.4 million, EBITDA $19.6 million); the current EV/EBITDA is 16.9.
What is Niagen Bioscience's return on equity?
Niagen Bioscience's return on equity (ROE) was 28.3% in fiscal 2025: net income of $17.4 million on average shareholders' equity of $61.3 million.
What is Niagen Bioscience's ROIC?
Niagen Bioscience's return on invested capital was 145.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Niagen Bioscience have?
Niagen Bioscience had total debt of $2.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.04 and more cash than debt.
Does Niagen Bioscience buy back its shares?
Yes. Niagen Bioscience spent $0.3 million on net share repurchases in fiscal 2025 Shares outstanding changed +7.2% over the year, to 85.4M..
What is Niagen Bioscience's free cash flow yield?
Niagen Bioscience generated $13.1 million of free cash flow in fiscal 2025, a free cash flow yield of 2.4% on its market value at year-end ($543.4 million).
What is Niagen Bioscience's current ratio?
Niagen Bioscience's current ratio was 4.86 at the end of fiscal 2025: current assets were 4.86 times current liabilities.